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OBJECTIVES: Post-transplantation hypertension is prevalent and is associated with increased cardiovascular
morbidity and subsequent graft dysfunction. The present study aimed to identify the factors associated with
arterial stiffness as measured by the ambulatory arterial stiffness index.
METHODS: The current study used a prospective, observational, analytical design to evaluate a group of adult
heart transplantation patients. Arterial stiffness was obtained by monitoring ambulatory blood pressure and
using the ambulatory arterial stiffness index as the surrogate outcome. Multivariate logistic regression analyses
were performed to control confounding.
RESULTS: In a group of 85 adult heart transplantation patients, hypertension was independently associated with
arterial stiffness (OR 4.98, CI 95% 1.06-23.4) as well as systolic and diastolic blood pressure averages and
nighttime descent.
CONCLUSIONS:Measurement of ambulatory arterial stiffness index is a new, non-invasive method that is easy to
perform, may contribute to better defining arterial stiffness prognosis and is associated with hypertension.
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’ INTRODUCTION
Globally, heart transplantation is indicated for the treatment
of heart failure refractory to clinical, surgical and interven-
tional treatments. Transplantation survival has improved
significantly in recent decades, mainly due to the emergence
of new immunosuppressants (1), which have also promoted
greater graft survival (2).
However, post-transplantation hypertension is a major
cardiovascular problem. The vasoconstrictor effect of immu-
nosuppressants, including cyclosporin, plays an impor-
tant role in generating this hypertension (1-3). Additionally,
denervation and the consequent increase in heart rate have
important implications for exercise, arterial stiffness, graft
vascular disease (GVD), acute rejection and other clinical
parameters (4,5). Furthermore, patients undergoing heart
transplantation present loss of modulation of blood pressure
and heart rate during sleep (6).
Data from the International Society for Heart and Lung
Transplantation (ISHLT) show that hypertension is present
in 50–90% of transplantation patients and is associated
with increased cardiovascular morbidity and mortality (7).
The Guidelines for the Care of Heart Transplant Recipients
specify the use of ambulatory blood pressure monitoring
(ABPM) as a class IIa recommendation and level C evidence
for assessing hypertension in patients referred for heart
transplantation (8,9). One consequence of hypertension is
increased arterial stiffness, which leads to cardiovascular
events, GVD and increased mortality in transplantation
patients (10).
Pulse wave velocity (PWV) and the augmentation index
(AIx) are the standard methods of assessing arterial stiffness.
However, the ambulatory arterial stiffness index (AASI),
derived from the ABPM (11), has been proposed as a new
indicator for risk and outcome prediction (12). Recent studies
have shown that the AASI can predict cardiovascular
morbidity and mortality and cerebrovascular accidents
(CVA) (12) and is also a strong predictor of incomplete block
of right branch (IBRB) in normotensive patients (12).
GVD remains the main late complication after heart trans-
plantation and is responsible for many deaths after the firstDOI: 10.6061/clinics/2016(09)02
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year post-transplantation. Furthermore, its association with
hypertension and arterial stiffness is well demonstrated (13,14).
Therefore, identifying risk factors, including hypertension,
for arterial stiffness in transplantation patients, especially
using a low-cost, no-risk method, may have clinical impor-
tance through identifying the best candidates for assessment.
There is a paucity of literature concerning the assessment of
arterial stiffness in the transplantation population, especially
with respect to heart transplantation.
This work aims to identify the factors associated with
arterial stiffness as measured by the AASI, thereby identify-
ing the prognostic utility of this methodology.
’ PATIENTS AND METHODS
Study outline
This study used a prospective, observational, analytical
design to measure arterial stiffness using a surrogate out-
come index, AASI, as measured by ABPM in heart trans-
plantation patients.
Study location
The present study was conducted at the Messejana
Heart and Lung Hospital, Ceará, Northeast Brazil. Data
were collected from March 2012 to June 2013. The patients
included in the study were followed until December 2014.
Population and sample
The study participants were adult patients who had under-
gone heart transplantation before June 2013. Although there
is information available in the literature on arterial stiffness
in hypertensive patients, most studies (15-17) have focused
on arterial stiffness in combination with other cardiovascular
diseases (15) and in renal transplantation recipients and
diabetic patients (18-20). In the current study, we hypothe-
sized that arterial stiffness would be present in patients with
potential predisposing factors such as hypertension and
chronological age. We recruited heart transplantation patients
who met the following inclusion criteria: adults (over
18 years of age) who underwent transplantation more than
6 months before enrollment. Patients who did not agree to
provide voluntary, informed consent were excluded from
participation. All adult patients identified during the study
period were invited to participate in the study, and a total of
97 patients were enrolled. Twelve patients were excluded for
reasons such as not providing consent, limited mobility,
living in another state and refusing to adhere to the planned
evaluations.
Variables
Clinical and laboratory data were stored in a special
clinical record and transported to a specific database. All
patients underwent clinical examination from March 2012
to June 2013 before being included in the study protocol.
The examination included a routine laboratory evaluation,
a clinical protocol with biochemical and hematological
examination and an evaluation of the dosage of immuno-
suppressants (cyclosporin serum, tacrolimus, sirolimus and
everolimus) obtained at time ‘‘0’’ from use.
Transthoracic echocardiography was performed for all
transplantation patients to evaluate graft function. Endo-
myocardial biopsy was performed at 1, 2, 3 and 6 months
post-transplantation, when the patient completed their first
year of transplantation, or at any time there was suspicion of
graft rejection. All analyses were conducted by the same
pathologist in the study institution following the ISHLT
classification.
Coronary angiography was performed on completion of
the first year after transplantation or at any time suspicion
of GVD arose. If more than 6 months elapsed since the
participant’s last coronary angiography, the procedure was
repeated. GVD was indicated by coronary angiography
showing at least a 50% lesion in a coronary artery. All
procedures were conducted at the study institution.
ABPM was performed for all patients for a 24-hour period.
The monitor used was a Meditechs ABPM 04 (Meditech
Ltd, Hungary), with a program specific for the calculation of
AASI. The measurement protocol followed the American
Hypertension Guidelines with 15/15-minute measurements
during the monitoring period and 30/30-minute measure-
ments during sleep, with monitoring starting at 7:00 hours
and ending at 22:59 hours. Abnormality criteria were map-
ped according to the guidelines. Analysis of ABPM and
AASI data was performed by a single doctor, who was
blinded to patient identification.
Statistical analysis
Distributions of continuous variables were described using
mean values and standard deviations. Categorical variables
were described by relative frequency categories. The normal-
ity of all numeric variables was tested using the Kolmo-
gorov-Smirnov test. The variables that showed an abnormal
distribution were transformed with Tukey’s ladder and the
best possible transformation was chosen.
An interaction test was used to identify possible multi-
plicative interactions between transplantation and hyperten-
sion in the development of arterial stiffness through a logistic
regression model. A bivariate analysis was performed with
parametric tests and simple regression models using arterial
stiffness as a binary variable. Finally, multiple logistic regres-
sion was performed to control confounding between deter-
minants with variables having p values up to 0.1 in the
bivariate analysis.
Ethics
The present study obtained approval from the Ethics and
Research Committee of the study institution under the
number 826/2011 and all enrolled patients provided written
informed consent.
’ RESULTS
The study group included 85 transplantation patients,
29 of whom presented with arterial stiffness. Univariate
analysis was performed to analyze the determinants of
arterial stiffness. After analyzing the patients’ comorbidities
and the impacts of diabetes, hypertension, peripheral artery
disease and coronary heart disease, it was found that all of
these factors are significantly related to arterial stiffness
(20.8%, 50%, 7.9%, and 46.1% if stiffness was present in a
patient versus 3.4%, 20.3%, 0, and 16.1% if not). Patient
gender and age did not appear to be related to arterial
stiffness (Table 1).
The patients’ laboratory evaluations indicated that creati-
nine levels were related to arterial stiffness (1.64 for patients
with arterial stiffness and 1.16 for patients without arterial
stiffness, po0.001), as well as levels of urea (p=0.006) and of
high-density cholesterol (p=0.015) (Table 2).
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Analysis of the ABPM data showed that average systolic
and diastolic blood pressure measurements were related to
the development of arterial stiffness (the mean systolic blood
pressure was 140.58 in the stiffness group and 123.25 in
the group without stiffness, po0.001). Systolic descent also
showed significance, as shown in Table 3 and Figure 1.
Heart transplantation-specific variables, especially GVD
and time from transplantation, were also associated with
arterial stiffness (Table 4).
Table 5 contains data regarding the use of immuno-
suppressive drugs by the patients with and without arterial
stiffness as measured by the AASI. Mycophenolate mofetil
use was associated with an increase in the occurrence of
stiffness (OR 2.91, CI 95% 1.04-8.15).
Finally, the multivariate analysis of the determinants
identified arterial stiffness as independently associated with
hypertension. Hypertension was over four times more
prevalent in transplantation patients with stiffness (OR 4.98,
CI 95% 1.06-23.4) and with an absence of diastolic nighttime
descent. Additionally, GVD (OR 14.9, CI 95% 2.0-107.5),
diabetes (OR 77.8, CI 95% 3.88-1561.4) and elevated
creatinine levels (OR 80.7, CI 95% 5.5-176.6) were highly
associated with arterial stiffness. All variables identified as
significant in the regression are presented in Table 6.
Table 1 - Univariate analysis results showing the relationships between sociodemographic variables, cardiomyopathies, comorbidities
and arterial stiffness index (n = 85)1.
Arterial stiffness - AASI
Yes No OR CI 95% p-value
Age (years) 58.4 (±8.3) 54.2 (±11.4) 0.95 0.91-1.00 0.061
Male 21 (88.3) 49 (80.2) 1.71 0.44-6.71 0.439
Myocardiopathy 0.092
Idiopathic 7 (29.3) 23 (38.1) 0.55 0.56-5.35 0.605
Chagasic 2 (8.2) 14 (23.3) 1.16 0.08-15.4 0.907
Ischemic 11 (45.8) 9 (15.2) 0.13 0.01-1.35 0.089
Valve 1 (4.2) 5 (8.2) 0.83 0.04-16.9 0.906
Alcoholic 2 (8.3) 4 (6.6) 0.33 0.02-5.02 0.427
Others 1 (4.1) 6 (10.2) 1 - -
Prior diabetes 5 (20.8) 2 (3.4) 7.76 1.39-43.3 0.019
Prior hypertension 12 (50.0) 12 (20.3) 4.08 1.47-11.3 0.007
Prior CAD 11 (46.1) 10 (16.1) 4.31 1.51-12.3 0.006
Prior PAD 2 (7.9) 0 (0.0) - - -
Prior PLD 8 (33.1) 5 (8.2) 5.60 1.61-19.5 0.007
1 The results are expressed in absolute and relative frequencies (%) for categorical variables and in means and standard deviations (± SD) for numeric
variables. CAD, coronary arterial disease; PAD, peripheral arterial disease; PLD, dyslipidemia.
Table 2 - Univariate analysis results showing the relationships between laboratory profiles and arterial stiffness index (n = 85)1.
Arterial stiffness – AASI
Yes No OR CI 95% p-value
Fasting blood glucose mg/dL 111.42 (±33.6) 100.0 (±21) 1.02 0.99-1.03 0.086
Glycated hemoglobin 6.19 (±1.27) 6.66 (±7.85) 0.98 0.88-1.09 0.716
Creatinine mg/dL 1.64 (±0.49) 1.16 (±0.26) 56.7 7.4-43.4 o0.001
Urea mg/dL 60.29 (±20.14) 47.64 (±15.94) 1.04 1.01-1.07 0.006
Total cholesterol mg/dL 182.75 (±57.48) 167.34 (±41.51) 1.01 0.99-1.02 0.174
LDL cholesterol mg/dL 93.34 (±28.97) 105.50 (±45.07 1.01 0.99-1.03 0.154
HDL cholesterol mg/dL 37.08 (±8.84) 44.13 (±12.05) 0.94 0.89-0.99 0.015
Triglycerides mg/dL 177.54 (±81.68) 141.49 (±73.64) 1.01 1.00-1.01 0.058
1 The results are expressed in absolute and relative frequencies (%) for categorical variables and in means and standard deviations (± SD) for numeric
variables. LDL, low-density cholesterol; HDL, high-density cholesterol.
Table 3 - Univariate analysis results showing the relationships between ABPM data and arterial stiffness index (n = 85)1.
Arterial stiffness – AASI
Yes No OR CI 95% p-value
Hypertension 18 (75.2) 13 (21.2) 11.1 3.65-33.5 o0.001
Average systolic BP mm/Hg 140.58 (±12.84) 123.25 (±10.97) 1.13 1.07-1.19 o0.001
Average diastolic BP mm/Hg 87.83 (±10.41) 80.30 (±7.72) 1.11 1.04-1.18 0.001
Systolic descent -1.54 (±5.36) 0.35 (±6.06) 0.94 0.87-1.03 0.002
Diastolic descent -26.17 (±108.27) 0.56 (±12.37) 0.98 0.95-1.01 0.174
Heart rate 91.41 (±9.19) 94 (±10.52) 1.03 0.98-1.08 0.263
1 The results are expressed in absolute and relative frequencies (%) for categorical variables and in means and standard deviations (± SD) for numeric
variables. BP, blood pressure.
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’ DISCUSSION
In recent years, arterial stiffness has been shown to be an
important marker of cardiovascular events and CVA in
the general population, especially in patients with chronic
kidney disease or diabetes (15,22). The AASI, a new measure
for determining arterial stiffness, was previously used to
show that arterial stiffness is associated with injury to target
organs and cardiovascular morbidity and mortality (15).
However, no studies have investigated using the AASI as a
marker of arterial stiffness in heart transplantation patients.
Our transplantation patients presented higher average
diastolic blood pressure and smaller nocturnal systolic descents
and diastolic levels than the normal population. These
factors are probably secondary to cardiac denervation and
the use of immunosuppressants and can lead to worsening
endothelial function in the transplantation population.
The literature shows that patients who have a normal
decrease in blood pressure during sleep have a reduction in
cardiac output with maintenance of peripheral resistance,
while heart transplantation patients have lower reductions
in cardiac output and in peripheral resistance due to a rela-
tive absence of nighttime descent (23). However, the litera-
ture does not report on what impact the absence of nighttime
descent has on the risk of arterial stiffness. Additionally,
blood pressure variables obtained through the ABPM (average
systolic and diastolic blood pressure, average systolic and
diastolic descent) were significant risk factors for increased
arterial stiffness, suggesting the importance of hypertension
as a determinant of arterial stiffness in transplantation
patients (24-26).
In a cohort of 330 renal transplantation patients, Mitchell
et al. observed significant increases in PWV (a marker of
Figure 1 - ABPM averages for transplantation patients with and
without the presence of arterial stiffness.
Table 4 - Univariate analysis results showing the relationships between post-transplantation variables and arterial stiffness index
(n = 85)1.
Arterial stiffness – AASI
Yes No OR CI 95% p-value
Graft vascular disease 8 (32.8) 6 (10.2) 4.42 1.33-14.7 0.015
Rejection 2 (18.2) 9 (28.1) 0.98 0.16-5.99 1.000
Ventricular dysfunction 4 (16.8) 9 (15.3) 4.58 0.67-31.2 0.282
Time to transplant 5.81 (±3.12) 4.16 (±3.34) 1.16 1.00-1.33 0.044
1 The results are expressed in absolute and relative frequencies (%) for categorical variables and in means and standard deviations (± SD) for numeric
variables.
Table 5 - Description of medications used in accordance with the index of arterial stiffness as measured by the ambulatory arterial
stiffness index (n = 85).
Arterial stiffness – AASI
Yes No OR CI 95% p-value
CORTICOID 2 (18.2) 9 (81.8) 0.51 0.10-2.58 0.420
MYCOPHENOLATE MOFETIL 10 (45.5) 12 (22.2) 2.91 1.04-8.15 0.041
MMS 12 (19.7) 49 (47.8) 0.26 0.09-0.75 0.012
CICLOSPORIN 14 (30.4) 32 (69.6) 1.26 0.4-3.2 0.625
TACROLIMUS 2 (11.8) 15 (88.2) 0.28 0.06-1.36 0.116
SIROLIMUS 5 (35.7) 9 (64.3) 1.49 0.44-5.01 0.519
EVEROLIMUS 4 (44.4) 5 (55.6) 2.16 0.52-8.85 0.285
Table 6 - Multivariate analysis results showing the relationships
between time of transplant data and arterial stiffness as
measured by the ambulatory arterial stiffness index (n = 85).
Variable OR CI 95% p-value
Median age 7.03 1.37-36.2 0.020
Hypertension 4.98 1.06-23.4 0.042
Prior diabetes 77.8 3.88-1561.4 0.004
Graft vascular disease 14.9 2.0-107.5 0.007
Diastolic descent 0.98 0.97-1.00 0.049
Creatinine
First tertile - - 0.003
Second tertile 12.9 1.09-154.6 0.043
Third tertile 80.7 5.54-176.6 0.001
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arterial stiffness) with age, systolic blood pressure and pulse
pressure. They concluded that PWV is a strong predictor of
all-cause mortality in the renal transplantation population
(po0.001) (27).
A number of publications and reviews of various physio-
pathological conditions have reported associations between
age, genetic factors, physical inactivity, smoking (28), obesity,
hypercholesterolemia (29), coronary artery disease, meta-
bolic syndrome, heart failure, stroke, chronic kidney disease,
rheumatoid arthritis, systemic lupus erythematosus and
vasculitis (30) and increased arterial stiffness.
Hypertension is strongly associated with an increased
risk of arterial stiffness (17). Other comorbidities also have
an important relationship with increased risk, as noted
in previous studies (31-33). In our study, comorbidities were
also associated with the development of arterial stiffness,
such as diabetes mellitus and dyslipidemia. Diabetes was the
most important factor associated with increased arterial
stiffness. A recent systematic review reported that there is
still no consensus on this association; thus, the current work
provides important support to strengthen the association (34).
Routine clinical applications for measuring arterial stiff-
ness may be expanded, as many studies have demonstrated
the predictive value of arterial stiffness for the risk of cardio-
vascular events and its mitigation through the use of anti-
hypertensive, antidiabetic and cholesterol-lowering drugs,
among others (35-36).
Our multivariate analysis showed that the association between
hypertension and arterial stiffness was not confounded by
other factors. Additionally, other independent factors were
identified, including diabetes mellitus, GVD and elevation of
creatinine levels (37,38).
The loss of renal function, measured as increased creati-
nine and urea levels, was the most important laboratory
factor identified for increased risk of arterial stiffness in
transplantation patients. This finding is consistent with the
literature (39-41). In another study, arterial stiffness was a
strong predictor of cardiovascular events in renal transplan-
tation recipients (42).
Multiple factors are involved in generating hypertension
in heart transplantation patients; these include immunosup-
pressive therapy, increased sensitivity of beta-adrenergic
receptors due to donor heart denervation, worsening of
endothelial function and drug nephrotoxicity (43,44).
GVD is the main complication of heart transplantation.
Identified risk factors for GVD include hypertension, obesity,
diabetes, and smoking. In our study, GVDwas related to arterial
stiffness, and its determinants were also associated (45).
Arterial stiffness is an independent predictor of cardio-
vascular events and all-cause mortality. The main risk factors
for arterial stiffness include hypertension, diabetes, dyslipi-
demia, and chronic kidney disease. Heart transplantation
patients who have these risk factors should be screened for
early development of arterial stiffness.
The data in the current study highlight the need for early
detection of hypertension and routine indication of ABPM in
heart transplantation patients with risk factors. Based on our
results, arterial stiffness should be analyzed using the AASI
or a similar evaluation method with the goal of early
intervention to reduce adverse events.
The present study was limited by the small number of
transplantation patients included. However, this is a unique
population, which by nature is difficult to select. Another
limitation was the lack of comparison between AASI arterial
stiffness measurements and another group measured using
standard methods such as the PWV or AIx, which may
have improved the accuracy of the analysis. However, for
heart transplantation patients as a specific group, our study
reached its goals of identifying a method of analysis for
arterial stiffness that is non-invasive, simple to perform and
easily adaptable for future studies.
This study concluded that hypertension was indepen-
dently associated with estimated arterial stiffness in a group
of adult heart transplantation patients. Renal dysfunction,
diabetes and absence of diastolic descent were identified as
determinants of arterial stiffness. Measuring the AASI offers
a new, non-invasive method that is easy to perform and is
indicative of hypertension. This method may assist in
defining therapeutic strategies for transplantation patients
and could contribute to improving prognosis.
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